Genzyme Begins Phase 2 Pivotal Study of Clolar® in Adult Acute Myelogenous Leukemia
Genzyme Corporation announced that it has begun treating patients in a phase 2 clinical trial examining the safety and effectiveness of Clolar® (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy.
This is Genzyme's second pivotal clinical study of clofarabine in adult patients with AML to commence this year, and it is expected to provide substantial support for expanding the current product label.
BIOMS MEDICAL BEGINS TRIAL OF TREATMENT FOR MS
BioMS Medical has announced that the first patients have been enrolled in its placebo-controlled, multicenter, Phase II clinical trial of MBP8298 for the treatment of relapsing-remitting multiple sclerosis (RRMS).
The 15-month, double-blind, placebo-controlled trial will enroll up to 215 patients with RRMS from up to 30 sites. The trial will be followed by a 12-month open-label extension period. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.
MBP8298 is also currently undergoing a pivotal Phase III trial for the treatment of secondary progressive multiple sclerosis (SPMS) patients with immune response genes HLA-DR2 and/or DR4.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment